Logo image of RANI

RANI THERAPEUTICS HOLDINGS-A (RANI) Stock Fundamental Analysis

NASDAQ:RANI - Nasdaq - US7530181004 - Common Stock - Currency: USD

0.6494  +0 (+0.2%)

Fundamental Rating

0

Overall RANI gets a fundamental rating of 0 out of 10. We evaluated RANI against 198 industry peers in the Pharmaceuticals industry. RANI has a bad profitability rating. Also its financial health evaluation is rather negative. RANI is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year RANI has reported negative net income.
In the past year RANI has reported a negative cash flow from operations.
RANI had negative earnings in each of the past 5 years.
RANI had a negative operating cash flow in each of the past 5 years.
RANI Yearly Net Income VS EBIT VS OCF VS FCFRANI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

RANI's Return On Assets of -123.52% is on the low side compared to the rest of the industry. RANI is outperformed by 79.29% of its industry peers.
Industry RankSector Rank
ROA -123.52%
ROE N/A
ROIC N/A
ROA(3y)-56.31%
ROA(5y)-39.33%
ROE(3y)-617.95%
ROE(5y)-378.96%
ROIC(3y)N/A
ROIC(5y)N/A
RANI Yearly ROA, ROE, ROICRANI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -500 -1K -1.5K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for RANI so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
RANI Yearly Profit, Operating, Gross MarginsRANI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 -1K -2K -3K -4K

More info and screens

0

2. Health

2.1 Basic Checks

RANI does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, RANI has more shares outstanding
Compared to 5 years ago, RANI has more shares outstanding
Compared to 1 year ago, RANI has a worse debt to assets ratio.
RANI Yearly Shares OutstandingRANI Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
RANI Yearly Total Debt VS Total AssetsRANI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

RANI has an Altman-Z score of -12.15. This is a bad value and indicates that RANI is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of RANI (-12.15) is worse than 75.25% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -12.15
ROIC/WACCN/A
WACC12.62%
RANI Yearly LT Debt VS Equity VS FCFRANI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M 60M

2.3 Liquidity

A Current Ratio of 0.88 indicates that RANI may have some problems paying its short term obligations.
Looking at the Current ratio, with a value of 0.88, RANI is doing worse than 84.85% of the companies in the same industry.
RANI has a Quick Ratio of 0.88. This is a bad value and indicates that RANI is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 0.88, RANI is doing worse than 78.79% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.88
Quick Ratio 0.88
RANI Yearly Current Assets VS Current LiabilitesRANI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

2

3. Growth

3.1 Past

RANI shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 23.26%, which is quite impressive.
RANI shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 0.96% yearly.
EPS 1Y (TTM)23.26%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%24.14%
Revenue 1Y (TTM)N/A
Revenue growth 3Y-27.7%
Revenue growth 5Y0.96%
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 13.16% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y9.16%
EPS Next 2Y15.25%
EPS Next 3Y19.72%
EPS Next 5Y13.16%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
RANI Yearly Revenue VS EstimatesRANI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2024 2025 2028 2029 2030 2031 2032 100M 200M 300M 400M 500M
RANI Yearly EPS VS EstimatesRANI Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 -1 2 3

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for RANI. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for RANI. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RANI Price Earnings VS Forward Price EarningsRANI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RANI Per share dataRANI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.2 -0.4 -0.6 -0.8

4.3 Compensation for Growth

RANI's earnings are expected to grow with 19.72% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y15.25%
EPS Next 3Y19.72%

More info and screens

0

5. Dividend

5.1 Amount

RANI does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

RANI THERAPEUTICS HOLDINGS-A

NASDAQ:RANI (5/23/2025, 9:37:59 AM)

0.6494

+0 (+0.2%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-13 2025-05-13/amc
Earnings (Next)N/A N/A
Inst Owners10.85%
Inst Owner Change-5.18%
Ins Owners1.5%
Ins Owner Change1.93%
Market Cap37.37M
Analysts85.45
Price Target11.22 (1627.75%)
Short Float %9.68%
Short Ratio11.27
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-6.69%
Min EPS beat(2)-7.31%
Max EPS beat(2)-6.08%
EPS beat(4)2
Avg EPS beat(4)3.59%
Min EPS beat(4)-7.31%
Max EPS beat(4)19.26%
EPS beat(8)5
Avg EPS beat(8)0.42%
EPS beat(12)9
Avg EPS beat(12)8.73%
EPS beat(16)13
Avg EPS beat(16)17.25%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-7.04%
PT rev (3m)-4.35%
EPS NQ rev (1m)0.86%
EPS NQ rev (3m)7.94%
EPS NY rev (1m)0%
EPS NY rev (3m)2.68%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 31.14
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.99
EYN/A
EPS(NY)-0.71
Fwd EYN/A
FCF(TTM)-0.6
FCFYN/A
OCF(TTM)-0.6
OCFYN/A
SpS0.02
BVpS-0.05
TBVpS-0.05
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -123.52%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-56.31%
ROA(5y)-39.33%
ROE(3y)-617.95%
ROE(5y)-378.96%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.05
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 29.2%
Cap/Sales 25.08%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.88
Quick Ratio 0.88
Altman-Z -12.15
F-Score3
WACC12.62%
ROIC/WACCN/A
Cap/Depr(3y)156.71%
Cap/Depr(5y)155.1%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)23.26%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%24.14%
EPS Next Y9.16%
EPS Next 2Y15.25%
EPS Next 3Y19.72%
EPS Next 5Y13.16%
Revenue 1Y (TTM)N/A
Revenue growth 3Y-27.7%
Revenue growth 5Y0.96%
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y25.21%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-3.88%
EBIT Next 3Y-5.54%
EBIT Next 5Y14.98%
FCF growth 1Y32.17%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y30.56%
OCF growth 3YN/A
OCF growth 5YN/A